Event Details
January 01, 1985
Description
FDA approval of Marinol and Cesamet
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| FDA | person | 0 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_024711.jpg
This document is page 75 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It details FDA regulations regarding 'off-label' prescriptions and specifically analyzes 'Cannabinoid-Based Drugs' such as Marinol, Syndros, Cesamet, Sativex, and Epidiolex. It discusses their scheduling under the Controlled Substances Act (CSA) and the status of their FDA approvals as of October 2017. The document bears a 'HOUSE_OVERSIGHT_024711' stamp, indicating it was part of a document production for the House Oversight Committee.
Related Events
Events with shared participants
FDA convened a meeting to analyze data on the drug Praluent, leading to its approval for a larger group of patients than expected.
Date unknown • U.S.
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
Marinol approved for treatment of anorexia associated with AIDS
1992-01-01 • USA
Syndros approved by the FDA
2016-01-01 • USA
FDA gave green light for Geron clinical trial.
2009-01-01 • US
FDA accepted GW Pharmaceuticals’ New Drug Application (NDA) for the cannabis-derived drug Epidiolex.
2017-10-01 • USA
FDA published industry guidance on botanical drug development.
2016-12-01 • USA
Previous FDA guidance on botanical drugs issued.
2004-06-01 • USA
FDA convened meeting to analyze drug data.
Date unknown
Expected FDA approval of a cannabis-derived pharmaceutical
2018-01-01 • USA
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event